Blog
RSS FeedPosted by Michael Wonder on 19 Jul 2024
DUSC utilisation analysis public release documents (June 2024)
19 July 2024 - The utilisation analysis public release documents from the June 2024 DUSC meeting are now available. ...
Posted by Michael Wonder on 19 Jul 2024
Outcome statement - June 2024 DUSC meeting
19 July 2024 - The outcome statement from the June 2024 DUSC meeting is now available. ...
Posted by Michael Wonder on 03 Jul 2024
Formulary coverage of brand name adalimumab and biosimilars across Medicare Part D plans
2 July 2024 - Adalimumab (Humira) is a top-selling drug in Medicare Part D, representing $4.7 billion of Medicare spending in ...
Posted by Michael Wonder on 22 Mar 2024
Outcome statement - February 2024 DUSC meeting
22 March 2024 - The Outcome Statement from the February 2024 DUSC meeting is now available. ...
Posted by Michael Wonder on 16 Dec 2023
Report on the collection of under co-payment data 2022-23
15 December 2023 - The report on the collection of under co-payment data 2022-23 is now available. ...
Posted by Michael Wonder on 14 Nov 2023
DUSC utilisation analysis public release documents (June 2023)
14 November 2023 - The utilisation analysis public release documents from the June 2023 DUSC meeting are now available. ...
Posted by Michael Wonder on 13 Nov 2023
Outcome statement - September 2023 DUSC meeting
13 November 2023 - The Outcome Statement from the September 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 20 Jul 2023
DUSC utilisation analysis public release documents (February 2023)
20 July 2023 - The utilisation analysis public release documents from the February 2023 DUSC meeting are now available. ...
Posted by Michael Wonder on 18 Jul 2023
Outcome statement - June 2023 DUSC meeting
18 July 2023 - The outcome statement from the June 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 12 Apr 2023
ASCO policy statement on biosimilar and interchangeable products in oncology
12 April 2023 - Given the current market dynamics and the regulatory landscape, this ASCO manuscript now seeks to propose several ...
Posted by Michael Wonder on 01 Apr 2023
Outcome statement - February 2023 DUSC meeting
31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 26 Dec 2022
Boom in scripts to fight depression
22 December 2022 - The explosion in popularity of the drugs comes despite warnings from psychiatrists that antidepressants should not be ...
Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 25 Oct 2022
DUSC utilisation analysis public release documents (October 2022)
25 October 2022 - The utilisation analysis public release documents from the June 2022 DUSC meeting are now available. ...
Posted by Michael Wonder on 24 Oct 2022
Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy
21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...